Tenax Therapeutics, INC

Tenax Therapeutics presented results from its LEVEL trial, which did not meet its primary endpoint but revealed significant biomarker improvements and a refined patient selection strategy for future development.

Tenax Therapeutics announced topline results from its Phase 3 LEVEL trial of TNX-103 for PH-HFpEF, which did not meet its primary endpoint for improving 6-minute walk distance.

Tenax Therapeutics announced its second quarter 2026 financial results, highlighting a strong cash position and providing an update on its pivotal Phase 3 LEVEL clinical trial, with topline data anticipated in August 2026.

Tenax Therapeutics will present results from its Phase 3 LEVEL clinical trial at the European Society of Cardiology (ESC) Congress 2026, with topline data expected in August 2026.

Tenax Therapeutics, Inc. has entered into a definitive Supply Agreement with Orion Corporation for its orally administered levosimendan product, alongside a Sixth Amendment to their existing License Agreement.

Tenax Therapeutics, Inc. has amended employment agreements for key executives, establishing severance and change-in-control benefits.

Tenax Therapeutics reports increased R&D spending for Phase 3 trials of levosimendan, with cash reserves projected to fund operations through Q2 2028.

Tenax Therapeutics reports a significant increase in R&D expenses for Q1 2026, driven by ongoing Phase 3 trials for levosimendan, while extending its cash runway into early 2028.

Tenax Therapeutics reported a significant increase in net loss for Q3 and the nine months ended September 30, 2025, driven by expanded clinical trial activities and higher operating expenses, while maintaining sufficient cash for operations through 2027.

Tenax Therapeutics reported increased cash reserves and accelerated R&D spending to advance its Phase 3 levosimendan program for pulmonary hypertension, despite widening net losses.

Tenax Therapeutics reports increased operating expenses and net loss for Q1 2025, offset by a strong cash position following recent equity offerings.

Tenax Therapeutics reports a significant increase in cash and cash equivalents to $98.3 million following a $99.7 million private placement, enabling the company to fund operations through 2027.

Tenax Therapeutics' 10-K filing reveals a significant increase in research and development expenses as the company progresses with its Phase 3 clinical trial for oral levosimendan.

Tenax Therapeutics' 10-K filing details its capital structure, recent reverse stock splits, and strategic focus on advancing its levosimendan program.

Declan Doogan, a Director of Tenax Therapeutics, Inc., purchased 53,000 shares of common stock on September 16, 2026 for $1.92 per share.

Christopher Thomas Giordano, CEO and a Director of Tenax Therapeutics, Inc., purchased 10,850 shares of common stock on September 11, 2026.

Thomas R Staab Ii, Chief Financial Officer of Tenax Therapeutics, Inc., purchased 5,675 shares of common stock on September 11, 2026 for $1.94 per share.

ADAR1 Capital Management, LLC and 1 other reported changes in beneficial ownership of Tenax Therapeutics, Inc. common stock on September 3, 2026.

ADAR1 Capital Management, LLC and 1 other reported changes in beneficial ownership of Tenax Therapeutics, Inc. common stock on August 31, 2026.

ADAR1 Capital Management, LLC and 1 other reported changes in beneficial ownership of Tenax Therapeutics, Inc. common stock on August 20, 2026.

Tenax Therapeutics, Inc. has announced its Annual Meeting of Stockholders will be held on June 2, 2026, to elect directors and ratify auditors.

Tenax Therapeutics has scheduled its 2025 Annual Meeting for June 11, 2025, and is seeking stockholder votes on several key proposals, including the election of directors and approval of amendments to the company's certificate of incorporation.

Tenax Therapeutics is holding its annual meeting on June 11, 2025, to vote on director elections, officer exculpation, stockholder action requirements, executive compensation, and auditor ratification.

Tenax Therapeutics is asking stockholders to approve an amendment to its 2022 Stock Incentive Plan to increase the number of shares authorized for issuance by 7,935,912 shares.

Tenax Therapeutics has hired Morrow Sodali to assist with proxy solicitation for its upcoming annual meeting on June 7, 2024.

Tenax Therapeutics has filed a definitive proxy statement with the SEC.

Tenax Therapeutics files an amendment to its S-1 registration statement related to a proposed public offering of common stock, warrants, and pre-funded warrants.

Tenax Therapeutics aims to raise up to $12 million through a public offering of common stock, warrants, and pre-funded warrants to advance its oral levosimendan (TNX-103) Phase 3 trial for pulmonary hypertension with heart failure and preserved ejection fraction (PH-HFpEF).

Christopher Thomas Giordano has filed an amendment to Schedule 13D, indicating an exit from his beneficial ownership of Tenax Therapeutics common stock.

ING Groep N.V. and ING Capital Markets LLC have filed a Schedule 13G, confirming they beneficially own 0% of Tenax Therapeutics, Inc. common stock as of September 11, 2026.

ADAR1 Capital Management, LLC and Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 14.0% of Tenax Therapeutics, Inc. common stock.

FMR LLC and Abigail P. Johnson have jointly filed an amended Schedule 13G, disclosing beneficial ownership of 1.4% of Tenax Therapeutics Inc.'s common stock as of August 31, 2026.

ING Groep N.V. and its subsidiary ING Capital Markets LLC have reported beneficial ownership of 7.05% of Tenax Therapeutics, Inc. common stock.

Sphera Funds Management Ltd. and its affiliates have reported a beneficial ownership of 5.33% in Tenax Therapeutics, Inc. common stock as of August 17, 2026.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported beneficial ownership of 5.8% of Tenax Therapeutics, Inc. common stock.